Featured Publications
Resistance Mechanisms to Anti-PD Cancer Immunotherapy
Vesely MD, Zhang T, Chen L. Resistance Mechanisms to Anti-PD Cancer Immunotherapy. Annual Review Of Immunology 2022, 40: 45-74. PMID: 35471840, DOI: 10.1146/annurev-immunol-070621-030155.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsAnti-PD therapyCancer immunotherapyMechanisms of resistanceImmune inhibitory moleculesFraction of patientsResistance mechanismsNormalization cancer immunotherapyAdditional immunotherapyPD-1Clinical evidenceAntigen presentationT cellsSolid tumorsTherapy resistanceH1 pathwayTumor microenvironmentImmunotherapyInhibitory moleculesHematopoietic malignanciesCancer treatmentTherapyPatientsCurrent studyCancer dataMalignancyCancer Immunoediting in the Era of Immuno-oncology.
Gubin MM, Vesely MD. Cancer Immunoediting in the Era of Immuno-oncology. Clinical Cancer Research 2022, 28: 3917-3928. PMID: 35594163, PMCID: PMC9481657, DOI: 10.1158/1078-0432.ccr-21-1804.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsCancer immunoeditingImmune-tumor cell interactionsCancer immunotherapyAbsence of immunotherapyDurable clinical responsesT cell biologyCell interactionsImmunotherapy resistanceClinical responseImmunosuppressive microenvironmentTumor immunogenicityImmuno-oncologyClinical dataPreclinical modelsImmunoeditingImmunotherapyHuman patientsImmune systemTumor microenvironmentCancerCancer progressionClinical subspecialtyImmunogenicityMicroenvironmentPatientsCancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting
Matsushita H, Vesely MD, Koboldt DC, Rickert CG, Uppaluri R, Magrini VJ, Arthur CD, White JM, Chen YS, Shea LK, Hundal J, Wendl MC, Demeter R, Wylie T, Allison JP, Smyth MJ, Old LJ, Mardis ER, Schreiber RD. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature 2012, 482: 400-404. PMID: 22318521, PMCID: PMC3874809, DOI: 10.1038/nature10755.Peer-Reviewed Original ResearchNatural Innate and Adaptive Immunity to Cancer
Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ. Natural Innate and Adaptive Immunity to Cancer. Annual Review Of Immunology 2011, 29: 235-271. PMID: 21219185, DOI: 10.1146/annurev-immunol-031210-101324.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsImmune systemAdaptive immune cell typesImmune cell typesTumor-promoting actionsHuman clinical dataNascent tumor cellsCancer immunosurveillanceClinical dataAdaptive immunityMouse modelTumor progressionCancerTumor cellsTumor suppressor mechanismImmunityEffector moleculesFurther studiesCell typesCompelling evidenceImportant defenseImmunotherapyImmunosurveillanceInnateProgression
2024
Up-regulated PLA2G10 in cancer impairs T cell infiltration to dampen immunity
Zhang T, Yu W, Cheng X, Yeung J, Ahumada V, Norris P, Pearson M, Yang X, van Deursen W, Halcovich C, Nassar A, Vesely M, Zhang Y, Zhang J, Ji L, Flies D, Liu L, Langermann S, LaRochelle W, Humphrey R, Zhao D, Zhang Q, Zhang J, Gu R, Schalper K, Sanmamed M, Chen L. Up-regulated PLA2G10 in cancer impairs T cell infiltration to dampen immunity. Science Immunology 2024, 9: eadh2334. PMID: 38669316, DOI: 10.1126/sciimmunol.adh2334.Peer-Reviewed Original ResearchConceptsT cell infiltrationT cell exclusionT cellsResistance to anti-PD-1 immunotherapyPoor T-cell infiltrationAnti-PD-1 immunotherapyImmunogenic mouse tumorsT cell mobilizationHuman cancer tissuesTherapeutic immunotherapyCancer immunotherapyMouse tumorsChemokine systemImmunotherapyTumor tissuesImpaired infiltrationTumorLipid metabolitesHuman cancersCancer tissuesInfiltrationA2 groupCancerPLA2G10Up-regulated
2013
Cancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy
Vesely MD, Schreiber RD. Cancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy. Annals Of The New York Academy Of Sciences 2013, 1284: 1-5. PMID: 23651186, PMCID: PMC3648872, DOI: 10.1111/nyas.12105.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsImmune systemTumor-specific antigensHuman cancer patientsTumor-promoting actionsNascent tumor cellsAntitumor immunityTumor immunityCancer immunosurveillanceChronic inflammationPersonalized cancer therapyImmunogenic variantsCancer immunotherapyCancer patientsCancer immunoeditingT cellsAnimal modelsTumor variantsTumor progressionTumor cellsCancer cellsImmunityCancer therapyCancerAntigenImmunoselection
2008
Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesis
Swann JB, Vesely MD, Silva A, Sharkey J, Akira S, Schreiber RD, Smyth MJ. Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesis. Proceedings Of The National Academy Of Sciences Of The United States Of America 2008, 105: 652-656. PMID: 18178624, PMCID: PMC2206591, DOI: 10.1073/pnas.0708594105.Peer-Reviewed Original ResearchConceptsCancer immunoeditingWT controlsAdaptor myeloid differentiation factor 88Myeloid differentiation factor 88Adaptive immune surveillanceMyD88-/- miceMyD88-deficient miceRole of TNFDMBA/TPAInflammation-induced cancerDistinct mouse modelsTNF-deficient miceInflammation-induced carcinogenesisO-tetradecanoylphorbol 13Mouse tumor modelsFactor 88WT miceChronic inflammationMCA sarcomaProinflammatory processesTumor immunologistsImmune surveillanceMouse modelSkin papillomasPrimary tumorigenesis